Mineralys Therapeutics, Inc. (MLYS)
(Delayed Data from NSDQ)
$11.76 USD
+0.17 (1.47%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $11.74 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Mineralys Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 31 | 19 | 3 | 0 |
Income After Depreciation & Amortization | -85 | -31 | -19 | -3 | 0 |
Non-Operating Income | 13 | 2 | -1 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -72 | -30 | -19 | -3 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -72 | -30 | -19 | -3 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -72 | -30 | -19 | -3 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -85 | -31 | -19 | -3 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -85 | -31 | -19 | -3 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 36.19 | 5.17 | 4.98 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.99 | -5.77 | -3.89 | NA | NA |
Diluted Net EPS (GAAP) | -1.99 | -5.77 | -3.89 | NA | NA |
Fiscal Year end for Mineralys Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 45.17 | 35.36 | 27.72 | 26.27 | 15.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | -45.17 | -35.36 | -27.72 | -26.27 | -15.73 |
Non-Operating Income | 4.15 | 3.85 | 3.32 | 3.51 | 3.59 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -41.01 | -31.51 | -24.39 | -22.76 | -12.14 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -41.01 | -31.51 | -24.39 | -22.76 | -12.14 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -41.01 | -31.51 | -24.39 | -22.76 | -12.14 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 49.36 | 44.90 | 40.09 | 39.93 | 39.76 |
Diluted EPS Before Non-Recurring Items | -0.83 | -0.70 | -0.61 | -0.57 | -0.31 |
Diluted Net EPS (GAAP) | -0.83 | -0.70 | -0.60 | -0.57 | -0.31 |